首页 > 最新文献

Mayo Clinic proceedings最新文献

英文 中文
Self-Monitoring of Blood Pressure and Feedback via Mobile App in Treatment of Uncontrolled Hypertension: the SMART-BP Randomized Clinical Trial.
IF 6.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-03-05 DOI: 10.1016/j.mayocp.2024.09.018
Minjae Yoon, Taeho Hur, Sung-Ji Park, Sang-Ho Jo, Eung Ju Kim, Soo-Joong Kim, Musarrat Hussain, Cam-Hao Hua, Sungyoung Lee, Dong-Ju Choi

Objective: To evaluate the effects of mobile apps with tailored recommendations on changes in blood pressure (BP) and drug adherence.

Patients and methods: This study is a randomized, open-label, multicenter trial to evaluate the efficacy of self-monitoring of BP (SMBP) with a mobile application-based feedback algorithm (SMBP app with feedback) compared with SMBP alone. Patients with uncontrolled hypertension aged 19 years or older were randomly assigned. In the control group, the patients only measured their BP at home using the mobile app combined with a Bluetooth BP monitor and received standard care, whereas in the intervention group, the patients could also receive alerts for BP measurement and additional recommendations from the app using a feedback algorithm in response to the obtained BP value. The primary end point was the change in mean home systolic BP at 24 weeks.

Results: From September 1, 2019, through July 8, 2020, 184 patients were randomized into 2 groups: SMBP app with feedback (n=97) and SMBP alone (n=87). At 24 weeks, the mean ± SD home systolic BP reduction from baseline was significantly greater in the SMBP app with feedback group than in the SMBP alone group (-22.4±13.5 vs -17.2±13.3 mm Hg; P=.02). The SMBP app with feedback group had higher drug adherence and proportion of adherence of 95% or greater than the SMBP alone group.

Conclusion: The SMBP app with feedback is superior to SMBP alone in terms of systolic BP reduction and improved drug adherence in patients with hypertension. Given the high cost of traditional interventions between patients and health care professionals, feedback through mobile apps could potentially be a useful tool in the management of hypertension.

Trial registration: clinicaltrials.gov Identifier: NCT04470284.

{"title":"Self-Monitoring of Blood Pressure and Feedback via Mobile App in Treatment of Uncontrolled Hypertension: the SMART-BP Randomized Clinical Trial.","authors":"Minjae Yoon, Taeho Hur, Sung-Ji Park, Sang-Ho Jo, Eung Ju Kim, Soo-Joong Kim, Musarrat Hussain, Cam-Hao Hua, Sungyoung Lee, Dong-Ju Choi","doi":"10.1016/j.mayocp.2024.09.018","DOIUrl":"https://doi.org/10.1016/j.mayocp.2024.09.018","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the effects of mobile apps with tailored recommendations on changes in blood pressure (BP) and drug adherence.</p><p><strong>Patients and methods: </strong>This study is a randomized, open-label, multicenter trial to evaluate the efficacy of self-monitoring of BP (SMBP) with a mobile application-based feedback algorithm (SMBP app with feedback) compared with SMBP alone. Patients with uncontrolled hypertension aged 19 years or older were randomly assigned. In the control group, the patients only measured their BP at home using the mobile app combined with a Bluetooth BP monitor and received standard care, whereas in the intervention group, the patients could also receive alerts for BP measurement and additional recommendations from the app using a feedback algorithm in response to the obtained BP value. The primary end point was the change in mean home systolic BP at 24 weeks.</p><p><strong>Results: </strong>From September 1, 2019, through July 8, 2020, 184 patients were randomized into 2 groups: SMBP app with feedback (n=97) and SMBP alone (n=87). At 24 weeks, the mean ± SD home systolic BP reduction from baseline was significantly greater in the SMBP app with feedback group than in the SMBP alone group (-22.4±13.5 vs -17.2±13.3 mm Hg; P=.02). The SMBP app with feedback group had higher drug adherence and proportion of adherence of 95% or greater than the SMBP alone group.</p><p><strong>Conclusion: </strong>The SMBP app with feedback is superior to SMBP alone in terms of systolic BP reduction and improved drug adherence in patients with hypertension. Given the high cost of traditional interventions between patients and health care professionals, feedback through mobile apps could potentially be a useful tool in the management of hypertension.</p><p><strong>Trial registration: </strong>clinicaltrials.gov Identifier: NCT04470284.</p>","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":" ","pages":""},"PeriodicalIF":6.9,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Contemporary Assessment of the Prevalence of Chronic Diseases That Contribute to Health Care Utilization.
IF 6.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-03-04 DOI: 10.1016/j.mayocp.2024.10.023
Harold I Salmons, Dirk R Larson, Rachel E Gullerud, Hilal Maradit Kremers, Jennifer L St Sauver, Arjun S Sebastian, Daniel J Berry, Jennifer J Westendorf, Matthew P Abdel

Objective: To investigate the most prevalent diagnosed conditions contributing to health care visitations in a defined US population by age and racial group, educational level, and socioeconomic deprivation.

Patients and methods: The Rochester Epidemiology Project is a medical records-linkage system that captures medical care provided to residents of Olmsted County, Minnesota. The Rochester Epidemiology Project was queried for all Olmsted County residents. International Classification of Diseases codes were obtained for individuals included in the project between January 1, 2014, and December 31, 2019, and they were categorized into 46 broad disease groups. Age- and sex-specific prevalences were estimated by dividing the number of individuals within each group by the corresponding population.

Results: In total, 154,254 individuals were included, and 122,627 (65,782 [53.6%] female) had at least one diagnosis of interest. Arthritis/joint disorders and back problems (ie, musculoskeletal disorders) were the most prevalent across all ages (42%), followed by skin (40%) and anxiety/depression/bipolar disorders (24%). Lower education and a higher area deprivation index score were associated with certain modifiable chronic diseases.

Conclusion: Musculoskeletal diseases were the most prevalent diagnosed conditions contributing to health care visitations within a defined US population. Individual level of education and socioeconomic deprivation were associated with modifiable diseases. An emphasis on effective diagnosis and management of musculoskeletal conditions in health care delivery models and more focused preventative efforts in disadvantaged communities are imperative.

{"title":"A Contemporary Assessment of the Prevalence of Chronic Diseases That Contribute to Health Care Utilization.","authors":"Harold I Salmons, Dirk R Larson, Rachel E Gullerud, Hilal Maradit Kremers, Jennifer L St Sauver, Arjun S Sebastian, Daniel J Berry, Jennifer J Westendorf, Matthew P Abdel","doi":"10.1016/j.mayocp.2024.10.023","DOIUrl":"https://doi.org/10.1016/j.mayocp.2024.10.023","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the most prevalent diagnosed conditions contributing to health care visitations in a defined US population by age and racial group, educational level, and socioeconomic deprivation.</p><p><strong>Patients and methods: </strong>The Rochester Epidemiology Project is a medical records-linkage system that captures medical care provided to residents of Olmsted County, Minnesota. The Rochester Epidemiology Project was queried for all Olmsted County residents. International Classification of Diseases codes were obtained for individuals included in the project between January 1, 2014, and December 31, 2019, and they were categorized into 46 broad disease groups. Age- and sex-specific prevalences were estimated by dividing the number of individuals within each group by the corresponding population.</p><p><strong>Results: </strong>In total, 154,254 individuals were included, and 122,627 (65,782 [53.6%] female) had at least one diagnosis of interest. Arthritis/joint disorders and back problems (ie, musculoskeletal disorders) were the most prevalent across all ages (42%), followed by skin (40%) and anxiety/depression/bipolar disorders (24%). Lower education and a higher area deprivation index score were associated with certain modifiable chronic diseases.</p><p><strong>Conclusion: </strong>Musculoskeletal diseases were the most prevalent diagnosed conditions contributing to health care visitations within a defined US population. Individual level of education and socioeconomic deprivation were associated with modifiable diseases. An emphasis on effective diagnosis and management of musculoskeletal conditions in health care delivery models and more focused preventative efforts in disadvantaged communities are imperative.</p>","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":" ","pages":""},"PeriodicalIF":6.9,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blood Pressure Time in Target Range Within 24 Hours and Cardiovascular Diseases and Mortality: Perspectives From a Real-World Cohort Study.
IF 6.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-03-04 DOI: 10.1016/j.mayocp.2024.08.012
Xue Tian, Yijun Zhang, Shuohua Chen, Xue Xia, Qin Xu, Yi Wang, Shouling Wu, Anxin Wang

Objective: To investigate the association of 24-hour, daytime, and nighttime ambulatory systolic blood pressure (SBP) time in target range (TTR) with the risk of cardiovascular disease (CVD) and mortality in real-world settings.

Patients and methods: Data were obtained from the Kailuan study. Systolic blood pressure TTR was calculated using linear interpolation, with 110 to 140 mm Hg as the target range. Cox regressions were performed to assess the associations of SBP TTR with outcomes.

Results: Among 5099 participants in this analysis, 396 cases of CVD (7.77%) and 490 cases of all-cause mortality (9.61%) occurred during a median follow-up of 6.96 years. After multivariable adjustment, each 1-SD increment in 24-hour SBP TTR was associated with an 11% lower risk of CVD (hazard ratio [HR], 0.89; 95% CI, 0.79 to 0.99; P=.008) and all-cause mortality (HR, 0.89; 95% CI, 0.81 to 0.98; P=.01). Consistently, each 1-SD increment in daytime SBP TTR was associated with 14% lower risk of CVD (HR, 0.86; 95% CI, 0.78 to 0.95; P=.005) and 13% lower risk of all-cause mortality (HR, 0.87; 95% CI, 0.79 to 0.95; P=.003). However, the associations for nighttime SBP TTR did not reach statistically significant levels.

Conclusion: Higher SBP TTR was associated with lower risk of CVD and mortality among Chinese adults in real-world settings. Efforts to attain SBP within 110 to 140 mm Hg over time may be an effective strategy to prevent CVD.

{"title":"Blood Pressure Time in Target Range Within 24 Hours and Cardiovascular Diseases and Mortality: Perspectives From a Real-World Cohort Study.","authors":"Xue Tian, Yijun Zhang, Shuohua Chen, Xue Xia, Qin Xu, Yi Wang, Shouling Wu, Anxin Wang","doi":"10.1016/j.mayocp.2024.08.012","DOIUrl":"https://doi.org/10.1016/j.mayocp.2024.08.012","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the association of 24-hour, daytime, and nighttime ambulatory systolic blood pressure (SBP) time in target range (TTR) with the risk of cardiovascular disease (CVD) and mortality in real-world settings.</p><p><strong>Patients and methods: </strong>Data were obtained from the Kailuan study. Systolic blood pressure TTR was calculated using linear interpolation, with 110 to 140 mm Hg as the target range. Cox regressions were performed to assess the associations of SBP TTR with outcomes.</p><p><strong>Results: </strong>Among 5099 participants in this analysis, 396 cases of CVD (7.77%) and 490 cases of all-cause mortality (9.61%) occurred during a median follow-up of 6.96 years. After multivariable adjustment, each 1-SD increment in 24-hour SBP TTR was associated with an 11% lower risk of CVD (hazard ratio [HR], 0.89; 95% CI, 0.79 to 0.99; P=.008) and all-cause mortality (HR, 0.89; 95% CI, 0.81 to 0.98; P=.01). Consistently, each 1-SD increment in daytime SBP TTR was associated with 14% lower risk of CVD (HR, 0.86; 95% CI, 0.78 to 0.95; P=.005) and 13% lower risk of all-cause mortality (HR, 0.87; 95% CI, 0.79 to 0.95; P=.003). However, the associations for nighttime SBP TTR did not reach statistically significant levels.</p><p><strong>Conclusion: </strong>Higher SBP TTR was associated with lower risk of CVD and mortality among Chinese adults in real-world settings. Efforts to attain SBP within 110 to 140 mm Hg over time may be an effective strategy to prevent CVD.</p>","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":" ","pages":""},"PeriodicalIF":6.9,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bullhead Sign in SAPHO Syndrome.
IF 6.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-03-03 DOI: 10.1016/j.mayocp.2025.01.006
Chrong-Reen Wang, Ta-Wei Tai, Nan-Tsing Chiu
{"title":"Bullhead Sign in SAPHO Syndrome.","authors":"Chrong-Reen Wang, Ta-Wei Tai, Nan-Tsing Chiu","doi":"10.1016/j.mayocp.2025.01.006","DOIUrl":"https://doi.org/10.1016/j.mayocp.2025.01.006","url":null,"abstract":"","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":" ","pages":""},"PeriodicalIF":6.9,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143542569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neutrophilic Dermatosis in Chronic Myelomonocytic Leukemia.
IF 6.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-03-03 DOI: 10.1016/j.mayocp.2024.09.030
Steven Tessier, Carilyn Wieland, Kebede Begna
{"title":"Neutrophilic Dermatosis in Chronic Myelomonocytic Leukemia.","authors":"Steven Tessier, Carilyn Wieland, Kebede Begna","doi":"10.1016/j.mayocp.2024.09.030","DOIUrl":"https://doi.org/10.1016/j.mayocp.2024.09.030","url":null,"abstract":"","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":" ","pages":""},"PeriodicalIF":6.9,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143542572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Body Fat Distribution and Ectopic Fat Accumulation as Mediator of Diabetogenic Action of Lipid-Modifying Drugs
IF 6.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-03-01 DOI: 10.1016/j.mayocp.2024.10.018
Yuanlong Hu MD , Xinhai Cui MD , Mengkai Lu MD , Xiuya Guan MD , Yuan Li MD , Lei Zhang MD, PhD , Lin Lin MD, PhD , Zhiyuan Zhang MD , Muxin Zhang MD , Jiaqi Hao MD , Xiaojie Wang MD , Jiaming Huan MD , Yunlun Li MD, PhD , Chao Li MD, PhD

Objective

To investigate the causal relationship between various lipid-modifying drugs and new-onset diabetes, as well as the mediators contributing to this relationship.

Methods

Mediation Mendelian randomization was performed to investigate the causal effect of lipid-modifying drug targets on type 2 diabetes (T2D) outcomes and the proportion of this association that is mediated through ectopic fat accumulation traits. Specific sets of variants in or near genes that encode 11 lipid-modifying drug targets (LDLR, HMGCR, NPC1L1, PCSK9, APOB, ABCG5/ABCG8, LPL, PPARA, ANGPTL3, APOC3, and CETP; for expansion of gene symbols, use search tool at www.genenames.org) were extracted. Random effects inverse variance weighted were performed to evaluate the causal effects among outcomes. Mediation analyses were performed to identify the mediators of the association between lipid-modifying drugs and T2D. The study was conducted from November 10, 2023, to April 2, 2024

Results

The genetic mimicry of HMGCR and APOB inhibition was associated with an increased T2D risk, whereas the genetic mimicry of LPL enhancement was linked to a lower T2D risk. Gluteofemoral adipose tissue volume was a mediator for explaining 9.52% (P=.002), 16.90% (P=.03), and 10.50% (P=.003) of the total effect of HMGCR, APOB, and LPL on T2D susceptibility, respectively. Liver fat was a mediator for explaining 21.12% (P=.005), 12.28% (P=.03), and 9.84% (P=.005) of the total effect of HMGCR, APOB, and LPL on T2D susceptibility, respectively.

Conclusion

Our findings support the hypothesis that liver fat and gluteofemoral adipose tissue play a mediating role in the prodiabetic effects of HMGCR and APOB inhibition, as well as in the antidiabetic effects of LPL enhancement.
{"title":"Body Fat Distribution and Ectopic Fat Accumulation as Mediator of Diabetogenic Action of Lipid-Modifying Drugs","authors":"Yuanlong Hu MD ,&nbsp;Xinhai Cui MD ,&nbsp;Mengkai Lu MD ,&nbsp;Xiuya Guan MD ,&nbsp;Yuan Li MD ,&nbsp;Lei Zhang MD, PhD ,&nbsp;Lin Lin MD, PhD ,&nbsp;Zhiyuan Zhang MD ,&nbsp;Muxin Zhang MD ,&nbsp;Jiaqi Hao MD ,&nbsp;Xiaojie Wang MD ,&nbsp;Jiaming Huan MD ,&nbsp;Yunlun Li MD, PhD ,&nbsp;Chao Li MD, PhD","doi":"10.1016/j.mayocp.2024.10.018","DOIUrl":"10.1016/j.mayocp.2024.10.018","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate the causal relationship between various lipid-modifying drugs and new-onset diabetes, as well as the mediators contributing to this relationship.</div></div><div><h3>Methods</h3><div>Mediation Mendelian randomization was performed to investigate the causal effect of lipid-modifying drug targets on type 2 diabetes (T2D) outcomes and the proportion of this association that is mediated through ectopic fat accumulation traits. Specific sets of variants in or near genes that encode 11 lipid-modifying drug targets (<em>LDLR</em><em>, HMGCR, NPC1L1, PCSK9, APOB, ABCG5/ABCG8, LPL, PPARA, ANGPTL3, APOC3</em>, and <em>CETP</em>; for expansion of gene symbols, use search tool at <span><span>www.genenames.org</span><svg><path></path></svg></span>) were extracted. Random effects inverse variance weighted were performed to evaluate the causal effects among outcomes. Mediation analyses were performed to identify the mediators of the association between lipid-modifying drugs and T2D. The study was conducted from November 10, 2023, to April 2, 2024</div></div><div><h3>Results</h3><div>The genetic mimicry of <em>HMGCR</em> and <em>APOB</em> inhibition was associated with an increased T2D risk, whereas the genetic mimicry of <em>LPL</em> enhancement was linked to a lower T2D risk. Gluteofemoral adipose tissue volume was a mediator for explaining 9.52% (<em>P</em>=.002), 16.90% (<em>P</em>=.03), and 10.50% (<em>P</em>=.003) of the total effect of <em>HMGCR, APOB</em>, and <em>LPL</em> on T2D susceptibility, respectively. Liver fat was a mediator for explaining 21.12% (<em>P</em>=.005), 12.28% (<em>P</em>=.03), and 9.84% (<em>P</em>=.005) of the total effect of <em>HMGCR, APOB,</em> and <em>LPL</em> on T2D susceptibility, respectively.</div></div><div><h3>Conclusion</h3><div>Our findings support the hypothesis that liver fat and gluteofemoral adipose tissue play a mediating role in the prodiabetic effects of <em>HMGCR</em> and <em>APOB</em> inhibition, as well as in the antidiabetic effects of <em>LPL</em> enhancement.</div></div>","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":"100 3","pages":"Pages 424-439"},"PeriodicalIF":6.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143365245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Charting a New Path Forward in Addressing Employee Well-being in Health Care
IF 6.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-03-01 DOI: 10.1016/j.mayocp.2024.11.018
Kaisa C. Wieneke MPH , Bridget E. Berkland MA, NBC-HWC , Gretl C. Kruse MS, MHA , Melissa R. Priestley MPA , Danielle M. Teal MAOL, PMP , Colin P. West MD, PhD
Health care worker well-being is critical to delivering optimal care to our patients. With greater understanding of these issues, evidence-informed models of employee well-being have been developed to guide efforts to improve well-being in the workplace. To ensure that organizational approaches resonate with staff needs, these models can be improved for local application by engaging employees in a co-creation process in which they actively participate in developing and refining the institutional framework for employee well-being. This article describes how the Mayo Clinic Employee Well-Being team, led by Mayo Clinic’s first organization-level medical director and administrator of Employee Well-Being, integrated employee input with existing well-being models through a comprehensive process to define a program structure reflecting the most important staff needs. The novel features of this approach are intended to serve as a guide for health care organizations as we work together to promote learning and working environments in medicine in which every member of the health care team can thrive.
{"title":"Charting a New Path Forward in Addressing Employee Well-being in Health Care","authors":"Kaisa C. Wieneke MPH ,&nbsp;Bridget E. Berkland MA, NBC-HWC ,&nbsp;Gretl C. Kruse MS, MHA ,&nbsp;Melissa R. Priestley MPA ,&nbsp;Danielle M. Teal MAOL, PMP ,&nbsp;Colin P. West MD, PhD","doi":"10.1016/j.mayocp.2024.11.018","DOIUrl":"10.1016/j.mayocp.2024.11.018","url":null,"abstract":"<div><div>Health care worker well-being is critical to delivering optimal care to our patients. With greater understanding of these issues, evidence-informed models of employee well-being have been developed to guide efforts to improve well-being in the workplace. To ensure that organizational approaches resonate with staff needs, these models can be improved for local application by engaging employees in a co-creation process in which they actively participate in developing and refining the institutional framework for employee well-being. This article describes how the Mayo Clinic Employee Well-Being team, led by Mayo Clinic’s first organization-level medical director and administrator of Employee Well-Being, integrated employee input with existing well-being models through a comprehensive process to define a program structure reflecting the most important staff needs. The novel features of this approach are intended to serve as a guide for health care organizations as we work together to promote learning and working environments in medicine in which every member of the health care team can thrive.</div></div>","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":"100 3","pages":"Pages 501-513"},"PeriodicalIF":6.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143529420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Leukocyte Cell–Derived Chemotaxin 2 (LECT2) Amyloidosis in the Liver
IF 6.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-03-01 DOI: 10.1016/j.mayocp.2024.11.007
Zongming Eric Chen MD, PhD
{"title":"Leukocyte Cell–Derived Chemotaxin 2 (LECT2) Amyloidosis in the Liver","authors":"Zongming Eric Chen MD, PhD","doi":"10.1016/j.mayocp.2024.11.007","DOIUrl":"10.1016/j.mayocp.2024.11.007","url":null,"abstract":"","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":"100 3","pages":"Page 412"},"PeriodicalIF":6.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143189879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pros and Cons of Upfront Quadruple Medical Therapy in Newly Diagnosed Heart Failure With Reduced Ejection Fraction
IF 6.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-03-01 DOI: 10.1016/j.mayocp.2024.12.005
Yogesh Reddy MBBS, Naveen L. Pereira MD
{"title":"Pros and Cons of Upfront Quadruple Medical Therapy in Newly Diagnosed Heart Failure With Reduced Ejection Fraction","authors":"Yogesh Reddy MBBS,&nbsp;Naveen L. Pereira MD","doi":"10.1016/j.mayocp.2024.12.005","DOIUrl":"10.1016/j.mayocp.2024.12.005","url":null,"abstract":"","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":"100 3","pages":"Pages 420-423"},"PeriodicalIF":6.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143528622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Verruciform Xanthoma
IF 6.9 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-03-01 DOI: 10.1016/j.mayocp.2024.12.009
Burak Tekin MD, Loren P. Herrera Hernandez MD, Lori A. Erickson MD
{"title":"Verruciform Xanthoma","authors":"Burak Tekin MD,&nbsp;Loren P. Herrera Hernandez MD,&nbsp;Lori A. Erickson MD","doi":"10.1016/j.mayocp.2024.12.009","DOIUrl":"10.1016/j.mayocp.2024.12.009","url":null,"abstract":"","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":"100 3","pages":"Pages 579-580"},"PeriodicalIF":6.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143529512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Mayo Clinic proceedings
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1